Q1 Earnings Forecast for Metagenomi Issued By HC Wainwright

Metagenomi, Inc. (NASDAQ:MGX) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of Metagenomi in a research report issued to clients and investors on Tuesday, May 27th. HC Wainwright analyst M. Kapoor anticipates that the company will earn ($0.66) per share for the quarter. HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Metagenomi’s current full-year earnings is ($2.46) per share. HC Wainwright also issued estimates for Metagenomi’s Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.75) EPS and Q4 2026 earnings at ($0.79) EPS.

Metagenomi (NASDAQ:MGX) last released its earnings results on Tuesday, May 13th. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.06). The company had revenue of $4.13 million for the quarter, compared to analyst estimates of $8.75 million. Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%.

A number of other brokerages have also recently issued reports on MGX. Wells Fargo & Company restated an “overweight” rating and issued a $16.00 price objective (down previously from $20.00) on shares of Metagenomi in a research note on Wednesday, May 14th. Wall Street Zen cut shares of Metagenomi from a “hold” rating to a “strong sell” rating in a research note on Thursday, May 22nd. Finally, Chardan Capital dropped their price objective on shares of Metagenomi from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, May 15th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat, Metagenomi has an average rating of “Moderate Buy” and a consensus price target of $13.00.

Metagenomi Price Performance

NASDAQ:MGX opened at $1.78 on Wednesday. Metagenomi has a one year low of $1.23 and a one year high of $6.90. The stock has a market cap of $66.54 million, a P/E ratio of -0.84 and a beta of -0.65. The company has a fifty day moving average price of $1.56 and a 200 day moving average price of $2.24.

Hedge Funds Weigh In On Metagenomi

A number of hedge funds have recently made changes to their positions in the business. Rhumbline Advisers grew its holdings in shares of Metagenomi by 123.3% in the 4th quarter. Rhumbline Advisers now owns 11,998 shares of the company’s stock worth $43,000 after purchasing an additional 6,626 shares during the last quarter. Corebridge Financial Inc. grew its holdings in shares of Metagenomi by 303.1% in the 4th quarter. Corebridge Financial Inc. now owns 13,602 shares of the company’s stock worth $49,000 after purchasing an additional 10,228 shares during the last quarter. Voya Investment Management LLC bought a new stake in shares of Metagenomi in the 4th quarter worth about $37,000. Price T Rowe Associates Inc. MD bought a new stake in shares of Metagenomi in the 4th quarter worth about $39,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Metagenomi by 338.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,193 shares of the company’s stock worth $55,000 after purchasing an additional 11,730 shares during the last quarter.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.